{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:12Z","timestamp":1786119492989,"version":"build-2736575974"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/coc.0b013e3181deb9e5","type":"journal-article","created":{"date-parts":[[2010,5,28]],"date-time":"2010-05-28T05:42:24Z","timestamp":1275025344000},"page":"S1-S7","source":"Crossref","is-referenced-by-count":12,"title":["Bone Continuum of Cancer"],"prefix":"10.1097","volume":"33","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009.","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R2-1-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3322\/CA.57.5.301","article-title":"Multiple myeloma: charging toward a bright future.","volume":"57","author":"Katzel","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R3-1-20210128","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1002\/cncr.22678","article-title":"Economic burden of metastatic bone disease in the U.S.","volume":"109","author":"Schulman","year":"2007","journal-title":"Cancer"},{"key":"R4-1-20210128","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease.","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"R5-1-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1634\/theoncologist.2007-0152","article-title":"Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"R6-1-20210128","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"R7-1-20210128","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"R8-1-20210128","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy.","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"R9-1-20210128","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity.","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"suppl 3","key":"R10-1-20210128","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0076","article-title":"NCCN Task Force Report: bone health in cancer care.","volume":"7","author":"Gralow","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"R11-1-20210128","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease.","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"R12-1-20210128","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3816\/SCT.2004.n.006","article-title":"The management of bone loss in patients with breast or prostate cancer.","volume":"1","author":"Mincey","year":"2004","journal-title":"Support Cancer Ther"},{"key":"R13-1-20210128","doi-asserted-by":"crossref","first-page":"6279s","DOI":"10.1158\/1078-0432.CCR-06-0681","article-title":"Treatment for myeloma bone disease.","volume":"12","author":"Yeh","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R15-1-20210128","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cncr.11147","article-title":"The development and function of the skeleton and bone metastases.","volume":"97","author":"Rodan","year":"2003","journal-title":"Cancer"},{"key":"R16-1-20210128","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis.","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"R17-1-20210128","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts.","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"R18-1-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"R19-1-20210128","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"key":"R20-1-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"R21-1-20210128","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1084\/jem.188.5.997","article-title":"TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.","volume":"188","author":"Fuller","year":"1998","journal-title":"J Exp Med"},{"key":"R22-1-20210128","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL.","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"R23-1-20210128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/bbrc.2000.3129","article-title":"Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria.","volume":"274","author":"O'Brien","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"R24-1-20210128","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro.","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"R25-1-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S8756-3282(99)00121-0","article-title":"A novel molecular mechanism modulating osteoclast differentiation and function.","volume":"25","author":"Yasuda","year":"1999","journal-title":"Bone"},{"key":"R26-1-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ncponc0381","article-title":"Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.","volume":"3","author":"Blair","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"R27-1-20210128","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities.","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R28-1-20210128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1677\/erc.1.00543","article-title":"Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.","volume":"12","author":"Clines","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"R29-1-20210128","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R30-1-20210128","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R31-1-20210128","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"R32-1-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer.","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"R33-1-20210128","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","article-title":"The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.","volume":"83","author":"Diamond","year":"1998","journal-title":"Cancer"},{"key":"R34-1-20210128","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"R35-1-20210128","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer.","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R36-1-20210128","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.urology.2007.09.018","article-title":"Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.","volume":"71","author":"Levy","year":"2008","journal-title":"Urology"},{"key":"R37-1-20210128","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","article-title":"Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.","volume":"63","author":"Smith","year":"2004","journal-title":"Urology"},{"key":"R38-1-20210128","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0022-5347(05)64985-3","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.","volume":"167","author":"Berruti","year":"2002","journal-title":"J Urol"},{"key":"R39-1-20210128","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0022-5347(05)00999-7","article-title":"Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.","volume":"175","author":"Morote","year":"2006","journal-title":"J Urol"},{"key":"R40-1-20210128","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/cncr.24404","article-title":"Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.","volume":"115","author":"Satoh","year":"2009","journal-title":"Cancer"},{"key":"R42-1-20210128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncpuro0995","article-title":"Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?","volume":"5","author":"Higano","year":"2008","journal-title":"Nat Clin Pract Urol"},{"key":"R43-1-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer.","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"R44-1-20210128","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00198-004-1799-7","article-title":"Fracture risk in patients with prostate cancer on androgen deprivation therapy.","volume":"16","author":"Lopez","year":"2005","journal-title":"Osteoporos Int"},{"key":"R45-1-20210128","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1464-410X.2007.07163.x","article-title":"Fracture risk in Danish men with prostate cancer: a nationwide register study.","volume":"100","author":"Abrahamsen","year":"2007","journal-title":"BJU Int"},{"key":"R46-1-20210128","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"R47-1-20210128","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.","volume":"175","author":"Smith","year":"2006","journal-title":"J Urol"},{"key":"R48-1-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","article-title":"Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma.","volume":"79","author":"Townsend","year":"1997","journal-title":"Cancer"},{"key":"R49-1-20210128","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.juro.2007.05.135","article-title":"Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.","volume":"178","author":"Krupski","year":"2007","journal-title":"J Urol"},{"key":"R50-1-20210128","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"R51-1-20210128","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"R52-1-20210128","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos Int"},{"key":"R53-1-20210128","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/S0959-8049(01)00317-3","article-title":"Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients: the effect of adjuvant clodronate treatment.","volume":"37","author":"Vehmanen","year":"2001","journal-title":"Eur J Cancer"},{"key":"R54-1-20210128","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","article-title":"Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer.","volume":"61","author":"Bruning","year":"1990","journal-title":"Br J Cancer"},{"key":"R55-1-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1742-7843.2008.00337.x","article-title":"The effect of aromatase inhibitors on bone metabolism.","volume":"104","author":"Folkestad","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R56-1-20210128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/GCO.0b013e32831da80e","article-title":"Aromatase inhibitors and bone health.","volume":"21","author":"Bundred","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R57-1-20210128","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2008.18.4184","article-title":"Cancer treatment-induced bone loss in breast and prostate cancer.","volume":"26","author":"Saad","year":"2008","journal-title":"J Clin Oncol"},{"key":"R58-1-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis.","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"R59-1-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.breast.2009.03.003","article-title":"The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.","volume":"18","author":"Hadji","year":"2009","journal-title":"Breast"},{"key":"R60-1-20210128","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdn762","article-title":"Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy.","volume":"20","author":"Hadji","year":"2009","journal-title":"Ann Oncol"},{"key":"R61-1-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3816\/CBC.2008.n.065","article-title":"The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.","volume":"8","author":"Jones","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"R62-1-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3816\/CBC.2006.n.021","article-title":"Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.","volume":"7","author":"Mincey","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"R63-1-20210128","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230).","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"R64-1-20210128","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","article-title":"Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.","volume":"26","author":"Eastell","year":"2008","journal-title":"J Clin Oncol"},{"key":"R66-1-20210128","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"R67-1-20210128","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer.","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"R68-1-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10911-005-5399-8","article-title":"Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.","volume":"10","author":"Kozlow","year":"2005","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"R69-1-20210128","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.","volume":"4","author":"Delea","year":"2006","journal-title":"J Support Oncol"},{"key":"R70-1-20210128","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3816\/SCT.2007.n.013","article-title":"Urinary N-telopeptide is a rapid predictor of response to and palliative benefit from bisphosphonate therapy in patients with metastatic breast cancer.","volume":"4","author":"Simmons","year":"2007","journal-title":"Support Cancer Ther"},{"key":"R71-1-20210128","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.","volume":"24","author":"Clemons","year":"2006","journal-title":"J Clin Oncol"},{"key":"R72-1-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"R73-1-20210128","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(05)67149-2","article-title":"Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.","volume":"164","author":"Berruti","year":"2000","journal-title":"J Urol"},{"key":"R74-1-20210128","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"R75-1-20210128","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer.","volume":"14","author":"Lage","year":"2008","journal-title":"Am J Manag Care"},{"key":"R76-1-20210128","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.bone.2008.05.003","article-title":"Incidence and risk factors for low trauma fractures in men with prostate cancer.","volume":"43","author":"Ahlborg","year":"2008","journal-title":"Bone"},{"key":"R77-1-20210128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.bjc.6602767","article-title":"Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.","volume":"93","author":"Berruti","year":"2005","journal-title":"Br J Cancer"},{"key":"R78-1-20210128","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.urology.2007.03.071","article-title":"Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.","volume":"70","author":"Smith","year":"2007","journal-title":"Urology"},{"key":"R79-1-20210128","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"R80-1-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R81-1-20210128","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.","volume":"12","author":"Cook","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R82-1-20210128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study.","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R83-1-20210128","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition.","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"R84-1-20210128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption.","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"key":"R85-1-20210128","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.1989.7.12.1909","article-title":"Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.","volume":"7","author":"Bataille","year":"1989","journal-title":"J Clin Oncol"},{"key":"R86-1-20210128","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2141.1997.1042920.x","article-title":"Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity.","volume":"97","author":"Diamond","year":"1997","journal-title":"Br J Haematol"},{"key":"R87-1-20210128","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"R88-1-20210128","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"R89-1-20210128","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"R90-1-20210128","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1182\/blood-2002-11-3385","article-title":"Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.","volume":"101","author":"Magrangeas","year":"2003","journal-title":"Blood"},{"key":"R91-1-20210128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2141.2004.04864.x","article-title":"Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma.","volume":"125","author":"Hashimoto","year":"2004","journal-title":"Br J Haematol"},{"key":"R92-1-20210128","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"R93-1-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.2000.01845.x","article-title":"Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts.","volume":"108","author":"Karadag","year":"2000","journal-title":"Br J Haematol"},{"key":"R94-1-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2141.1998.00687.x","article-title":"Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.","volume":"101","author":"Sati","year":"1998","journal-title":"Br J Haematol"},{"key":"R95-1-20210128","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"R96-1-20210128","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells.","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"R97-1-20210128","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"R98-1-20210128","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"key":"R99-1-20210128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00774-008-0012-z","article-title":"Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.","volume":"27","author":"Abe","year":"2009","journal-title":"J Bone Miner Metab"},{"key":"R100-1-20210128","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R101-1-20210128","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"R103-1-20210128","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.juro.2007.08.137","article-title":"Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.","volume":"179","author":"Smith","year":"2008","journal-title":"J Urol"},{"key":"R104-1-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10549-005-5701-x","article-title":"Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women.","volume":"93","author":"Erkkola","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"R105-1-20210128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3322\/CA.2008.0002","article-title":"Management of complications of prostate cancer treatment.","volume":"58","author":"Michaelson","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"R106-1-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/PPO.0b013e318161d32d","article-title":"Current trials using bone-targeting agents in prostate cancer.","volume":"14","author":"Tu","year":"2008","journal-title":"Cancer J"},{"key":"R107-1-20210128","doi-asserted-by":"crossref","first-page":"6296s","DOI":"10.1158\/1078-0432.CCR-06-0929","article-title":"Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.","volume":"12","author":"Carducci","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201006001-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:25:04Z","timestamp":1786040704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201006001-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181deb9e5","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}